Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer

Y. Otani, M. Kimata, N. Igarashi, T. Kubota, M. Kitajima, M. Fujii, Kaori Kameyama, Y. Okada

Research output: Contribution to journalArticle

Abstract

The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading components of the extracellular matrix including collagens, laminin, proteoglycan, fibronectin, and others. In some human GI tract cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. Numerous reports concerning the role of MMPs during cancer invasion and metastasis have been published. Based on this, inhibition of MMPS has in recent years been recognized as a therapeutic target of particular interest. In order to evaluate the therapeutic effects of MMPI, we have established a nude mouse peritoneal dissemination model. Two MMPIs, matlystatin and marimastat, have been found to inhibit peritoneal dissemination formation. Recent advances in MMP research and reports on the clinical application of MMPIs are reviewed in this paper.

Original languageEnglish
Pages (from-to)679-685
Number of pages7
JournalBiotherapy
Volume13
Issue number6
Publication statusPublished - 1999

Fingerprint

Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Gastrointestinal Tract
MMPI
Neoplasms
Neoplasm Metastasis
Endopeptidases
Laminin
Therapeutic Uses
Proteoglycans
Therapeutics
Fibronectins
Nude Mice
Extracellular Matrix
Zinc
Collagen
Membranes
Enzymes

Keywords

  • Invasion
  • Marimastat
  • Matlystatin
  • Matrix metalloproteinase inhibitor
  • Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Otani, Y., Kimata, M., Igarashi, N., Kubota, T., Kitajima, M., Fujii, M., ... Okada, Y. (1999). Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer. Biotherapy, 13(6), 679-685.

Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer. / Otani, Y.; Kimata, M.; Igarashi, N.; Kubota, T.; Kitajima, M.; Fujii, M.; Kameyama, Kaori; Okada, Y.

In: Biotherapy, Vol. 13, No. 6, 1999, p. 679-685.

Research output: Contribution to journalArticle

Otani, Y, Kimata, M, Igarashi, N, Kubota, T, Kitajima, M, Fujii, M, Kameyama, K & Okada, Y 1999, 'Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer', Biotherapy, vol. 13, no. 6, pp. 679-685.
Otani Y, Kimata M, Igarashi N, Kubota T, Kitajima M, Fujii M et al. Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer. Biotherapy. 1999;13(6):679-685.
Otani, Y. ; Kimata, M. ; Igarashi, N. ; Kubota, T. ; Kitajima, M. ; Fujii, M. ; Kameyama, Kaori ; Okada, Y. / Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer. In: Biotherapy. 1999 ; Vol. 13, No. 6. pp. 679-685.
@article{a1cae6f7ee4f43f3b2ae7f2970439824,
title = "Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer",
abstract = "The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading components of the extracellular matrix including collagens, laminin, proteoglycan, fibronectin, and others. In some human GI tract cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. Numerous reports concerning the role of MMPs during cancer invasion and metastasis have been published. Based on this, inhibition of MMPS has in recent years been recognized as a therapeutic target of particular interest. In order to evaluate the therapeutic effects of MMPI, we have established a nude mouse peritoneal dissemination model. Two MMPIs, matlystatin and marimastat, have been found to inhibit peritoneal dissemination formation. Recent advances in MMP research and reports on the clinical application of MMPIs are reviewed in this paper.",
keywords = "Invasion, Marimastat, Matlystatin, Matrix metalloproteinase inhibitor, Metastasis",
author = "Y. Otani and M. Kimata and N. Igarashi and T. Kubota and M. Kitajima and M. Fujii and Kaori Kameyama and Y. Okada",
year = "1999",
language = "English",
volume = "13",
pages = "679--685",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Matrix metalloproteinase inhibitors (MMPI) and their therapeutic application for GI tract cancer

AU - Otani, Y.

AU - Kimata, M.

AU - Igarashi, N.

AU - Kubota, T.

AU - Kitajima, M.

AU - Fujii, M.

AU - Kameyama, Kaori

AU - Okada, Y.

PY - 1999

Y1 - 1999

N2 - The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading components of the extracellular matrix including collagens, laminin, proteoglycan, fibronectin, and others. In some human GI tract cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. Numerous reports concerning the role of MMPs during cancer invasion and metastasis have been published. Based on this, inhibition of MMPS has in recent years been recognized as a therapeutic target of particular interest. In order to evaluate the therapeutic effects of MMPI, we have established a nude mouse peritoneal dissemination model. Two MMPIs, matlystatin and marimastat, have been found to inhibit peritoneal dissemination formation. Recent advances in MMP research and reports on the clinical application of MMPIs are reviewed in this paper.

AB - The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading components of the extracellular matrix including collagens, laminin, proteoglycan, fibronectin, and others. In some human GI tract cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. Numerous reports concerning the role of MMPs during cancer invasion and metastasis have been published. Based on this, inhibition of MMPS has in recent years been recognized as a therapeutic target of particular interest. In order to evaluate the therapeutic effects of MMPI, we have established a nude mouse peritoneal dissemination model. Two MMPIs, matlystatin and marimastat, have been found to inhibit peritoneal dissemination formation. Recent advances in MMP research and reports on the clinical application of MMPIs are reviewed in this paper.

KW - Invasion

KW - Marimastat

KW - Matlystatin

KW - Matrix metalloproteinase inhibitor

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=0032772156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032772156&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032772156

VL - 13

SP - 679

EP - 685

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 6

ER -